Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Researchers receive $1M grant to train Native American communities improve their health

UC Davis School of Medicine researchers will train Native American communities in Northern California to develop and implement culturally appropriate interventions to improve their health by decreasing obesity and type-2 diabetes, through a $1 million research grant from the National Institute of Diabetes and Kidney Diseases of the National Institutes of Health.

11 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Researchers examine differences in eating habits of African Americans

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

Tufts University faculty debunks common dental myths

Brushing, flossing, and twice-yearly dental check-ups are standard for oral health care, but there are more health benefits to taking care of your pearly whites than most of us know. In a review article, a faculty member at Tufts University School of Dental Medicine (TUSDM) debunks common dental myths and outlines how diet and nutrition affects oral health in children, teenagers, expectant mothers, adults and elders.

7 Aug 2010

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes, Inc. today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010.

7 Aug 2010

Survey reveals need for nutrition education among African Americans for disease prevention, management

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites, according to federal health agencies. Obesity is a leading risk factor for development of diabetes, a condition that results when the body cannot properly use insulin to transfer sugar from the blood to muscle and fat cells that use glucose for energy.

6 Aug 2010

Australia has highest rates of type 1 diabetes among children

Australia ranks the highest among 10 OECD countries when it comes to rate of type 1 diabetes among children, according to the Australian Institute of Health and Welfare (AIHW). The OECD or consists of 32 countries.

5 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010